Citations

Showing 10 of 107964 citations.

QTc Values Among Children and Adolescents Presenting to the Emergency Department
Dorn, Charlotte S. Van , Johnson, Jonathan N. , Taggart, Nathaniel W. , Thorkelson, Lois A., Ackerman, Michael J. , Taggart, Nathaniel W

Mayo Clinic

Pediatrics | November 29, 2011 | Volume: 128 | Issue: 6 | Pages: e1395-e1401

10.1542/peds.2010-1513 | PMID 22123891 Get It

OBJECTIVE: Long-QT syndrome (LQTS) is both underdiagnosed and overdiagnosed. Many patients are incorrectly diagnosed as having LQTS after presenting to an emergency department (ED) with presyncope/syncope and demonstrating “borderline” QT-interval prolongation (QTc ≥ 440 milliseconds) in a sentinel ED-obtained electrocardiogram (ECG). We sought to evaluate the distribution and clinical significance of QT intervals in the ED. METHODS: We retrospectively reviewed data for all patients 22 years of age or younger (N = 626; 369 females; age, mean ± SD: 17 ± 5 years) who had ECGs obtained in our ED between July 1, 2007, and June 30, 2008. A total of 223 patients were excluded because of known structural heart disease, arrhythmias, electrolyte abnormalities, or exposure to QT-interval–prolonging medications. RESULTS: The average QTc was 428 ± 28 milliseconds (range: 344–566 milliseconds), and approximately one-third of patients had QTc values of ≥440 milliseconds (females: 41%; males: 21%). Overall, 104 patients presented with presyncope/syncope, of whom 14 (13%) had follow-up ECGs. On follow-up, these patients demonstrated significant decreases in QTc values of 33 ± 43 milliseconds (P < .04). Only 8 (31%) of 26 patients with presyncope/syncope with borderline QT values had follow-up ECGs performed, in 5 of which the QTc values were decreased significantly. No patients ultimately received LQTS diagnoses. CONCLUSIONS: In the ED setting, approximately one-third of pediatric patients exhibited QTc values of ≥440 milliseconds and had significant normalization of QTc values in follow-up evaluations. First-time ECGs obtained after a syncopal episode must be interpreted with caution, particularly in the context of so-called borderline QT intervals.
Response to Letter Regarding Article, “Impact of Cardiac Rehabilitation on Mortality and Cardiovascular Events After Percutaneous Coronary Intervention in the Community”
Tilbury, R. Thomas, Squires, Ray W. , Thomas, Randal J. , Lennon, Ryan J. , Goel, Kashish , Thomas, Randal

Mayo Clinic

Circulation | November 28, 2011 | Volume: 124 | Issue: 22 | Pages: No page available

10.1161/circulationaha.111.061713 Get It

Left Main Coronary Artery to Biatrial Fistula Associated With Severe Functional Mitral Valve Regurgitation
Suri, Rakesh M. , Okoh, Alexis , Espinosa, Raúl E. , Breen, Jerome F., Rehfeldt, Kent H., Nishimura, Rick A.

Mayo Clinic

Circulation | November 28, 2011 | Volume: 124 | Issue: 22 | Pages: 2456-2457

10.1161/circulationaha.111.032706 | PMID 22125191 Get It

A 71-Year-Old Woman with Multiple Myeloma Status after Stem Cell Transplantation
Zeldenrust, Steven R., Murray, David , Katzmann, Jerry A., Donato, Leslie J.

Mayo Clinic

Clinical Chemistry | November 28, 2011 | Volume: 57 | Issue: 12 | Pages: 1645-1648

10.1373/clinchem.2011.163766 | PMID 22125317 Get It

Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer
Dyar, Stephen, Moreno‐Aspitia, Alvaro

Mayo Clinic

Breast Cancer: Basic and Clinical Research | November 28, 2011 | Volume: 5 | Issue: No issue available | Pages: BCBCR.S7379

10.4137/bcbcr.s7379 | PMID 22174585 Get It

There is an ongoing need for development of new chemotherapeutic regimens for metastatic breast cancer [mBC], especially when tumors lack therapeutic targets such as the estrogen or progesterone receptor [ER/PR], or the human epidermal growth factor receptor-2 [HER2]. Capecitabine is an orally bioavailable fluoropyrimidine approved for monotherapy in mBC, and bevacizumab is a monoclonal antibody targeting vascular endothelial growth factor which has shown to be active in mBC and tolerable in combination with other chemotherapeutics. The combination of these two agents has been explored in multiple phase II and III clinical studies, with improvements in progression-free survival and overall response rates noted as compared to capecitabine monotherapy. However, the use of bevacizumab in combination with capecitabine and other chemotherapy agents for mBC remains beset with controversy due to safety concerns, cost issues, and pending regulatory decisions.
Aurora B hyperactivation by Bub1 overexpression promotes chromosome missegregation
Ricke, Robin M., Deursen, Jan M. van

Mayo Clinic

Cell Cycle | November 28, 2011 | Volume: 10 | Issue: 21 | Pages: 3645-3651

10.4161/cc.10.21.18156 | PMID 22033440 Get It

Effectiveness of a Multidisciplinary Worksite Stress Reduction Programme for Women
Werneburg, Brooke L., Herman, Lacie L., Preston, Heather R., Rausch, Sarah M., Warren, Beth A., Olsen, Kerry D., Clark, Matthew M.

Mayo Clinic

Stress and Health | November 28, 2011 | Volume: 27 | Issue: 5 | Pages: 356-364

10.1002/smi.1380 Get It

AbstractIt has been well established that a high level of stress is associated with medical problems, mental health difficulties and absenteeism at the workplace. The aim of this single‐arm study design was to examine the potential effectiveness of a 12‐session multidisciplinary stress reduction programme on reducing perceived stress and improving health behaviours and quality of life. One hundred and four women participated in a programme that incorporated group support, skill building and cognitive behavioural and relaxation techniques. A series of Bonferroni corrected t‐tests found that the participants reported having significantly (p < 0.001) lower levels of perceived stress, improved health behaviours (sleep, nutrition, physical activity) improved overall health and improved quality of life at the end of the 12 week programme and at 1‐month follow‐up. Although the effect sizes for improvement were all large, there was no control group, so regression to the mean or selection bias may have impacted the results. Therefore, these results provide initial support for the implementation of gender‐based worksite stress reduction programmes and provide guidance in designing an effective worksite stress reduction programme. Further research using randomized controlled trials is warranted. Copyright © 2011 John Wiley & Sons, Ltd.
Transfusion-related acute lung injury: incidence and risk factors
Toy, Pearl, Bacchetti, Peter , Looney, Mark R. , Gropper, Michael A. , Hubmayr, Rolf D., Lowell, Clifford A. , Norris, Philip J. , Murphy, Edward L. , Weiskopf, Richard B. , Wilson, Gregory , Koenigsberg, Monique, Lee, Deanna, Schuller, Randy M. , Wu, Ping , Grimes, Barbara , Winters, Jeffrey L. , Mair, David , Hirschler, Nora V., Rosen, Rosa Sanchez, Matthay, Michael A. , Group, for the TRALI Study, Gajic, Ognjen , Gandhi, Manish J. , Group, for the TRALI Study, Winters, Jeffrey L

Mayo Clinic

Blood | November 24, 2011 | Volume: 119 | Issue: 7 | Pages: 1757-1767

10.1182/blood-2011-08-370932 | PMID 22117051 Get It

AbstractTransfusion-related acute lung injury (TRALI) is the leading cause of transfusion-related mortality. To determine TRALI incidence by prospective, active surveillance and to identify risk factors by a case-control study, 2 academic medical centers enrolled 89 cases and 164 transfused controls. Recipient risk factors identified by multivariate analysis were higher IL-8 levels, liver surgery, chronic alcohol abuse, shock, higher peak airway pressure while being mechanically ventilated, current smoking, and positive fluid balance. Transfusion risk factors were receipt of plasma or whole blood from female donors (odds ratio = 4.5, 95% confidence interval [CI], 1.85-11.2, P = .001), volume of HLA class II antibody with normalized background ratio more than 27.5 (OR = 1.92/100 mL, 95% CI, 1.08-3.4, P = .03), and volume of anti–human neutrophil antigen positive by granulocyte immunofluoresence test (OR = 1.71/100 mL, 95% CI, 1.18-2.5, P = .004). Little or no risk was associated with older red blood cell units, noncognate or weak cognate class II antibody, or class I antibody. Reduced transfusion of plasma from female donors was concurrent with reduced TRALI incidence: 2.57 (95% CI, 1.72-3.86) in 2006 versus 0.81 (95% CI, 0.44-1.49) in 2009 per 10 000 transfused units (P = .002). The identified risk factors provide potential targets for reducing residual TRALI.
Surgeon radiation exposure in cone beam computed tomography‐based, image‐guided spinal surgery
Nottmeier, Eric W. , Bowman, Cammi, Nelson, Kevin L.

Mayo Clinic

The International Journal of Medical Robotics and Computer Assisted Surgery | November 24, 2011 | Volume: 8 | Issue: 2 | Pages: 196-200

10.1002/rcs.450 | PMID 22114012 Get It

AbstractBackgroundRadiation exposure to the surgeon is a concern in spinal surgery, especially with the increasing popularity of minimally invasive spinal surgery techniques. Three‐dimensional (3D) image guidance used in conjunction with cone beam computed tomography (cbCT) has a theoretical advantage of decreased radiation exposure to the surgeon and operating room (OR) staff. Radiation scatter to the environment immediately surrounding a CT scanner during acquisition of a CT scan is a known entity. This in vivo study measures the radiation exposure to the surgeon when using cbCT registration in 3D image‐guided spinal surgery.MethodsTwo badge dosimeters were worn by the surgeon (EWN), one on the right waistband of the surgeon's scrubs and the other located over the thyroid area during 25 consecutive spinal surgery cases in which cbCT was used in conjunction with 3D image guidance. No lead protection was worn by the surgeon. The cbCT device was used for registration of the anatomy and to confirm adequate instrumentation placement. The surgeon stood behind a clear lead shield in the same location during every spin of the cbCT device. After the 25th case, the badge dosimeters were sent to the radiology department for analysis.ResultsOverall, 63 cbCT spins were accomplished in 25 patients. A total of 228 screws were placed into spinal levels spanning from C2 to the ileum. No complications resulted from instrumentation placement or the use of image guidance.Analysis of both badge dosimeters revealed 0 millirem (mRem) exposure.ConclusionsOur study demonstrates that no radiation exposure to the surgeon occurs in cbCT‐based, 3D image‐guided spinal surgery procedures. Additionally, radiation scatter does not result in surgeon radiation exposure during patient registration if the surgeon stands behind a lead shield 10 feet from the cbCT device and not in direct line with the opening of the cbCT tube. Copyright © 2011 John Wiley & Sons, Ltd.
GH Does Not Modulate the Early Fasting-Induced Release of Free Fatty Acids in Mice
Steyn, Frederik J. , Leong, J. W., Huang, Lili , Tan, H. Y. , Xie, T. Y. , NELSON, CARL, Waters, Michael J. , Veldhuis, Johannes D. , Epelbaum, Jacques, Chen, Chen , Steyn, F J , Chen, C

Mayo Clinic

Endocrinology | November 23, 2011 | Volume: 153 | Issue: 1 | Pages: 273-282

10.1210/en.2011-1681 | PMID 22109889 Get It

Fasting results in the mobilization of adipose stores and the elevation of levels of free fatty acids (FFA). In humans, this process is driven by a release in GH. Little is known regarding the role of GH in modulating this process during early stages of fasting in the mouse. Confirmation of the role of GH in modulating FFA release in the fasting mouse is of particular importance given the frequent use of mouse models to study metabolic mechanisms. Here, we correlate the initial release of FFA throughout fasting in mice with pulsatile GH secretion. Observations illustrate the rapid release of FFA in response to food withdrawal. This does not correlate with a rise in GH secretion. Rather, we observed a striking loss in pulsatile secretion of GH throughout the first 6 h of fasting, suggesting that GH does not modulate the initial release of FFA in the mouse in response to fasting. This was confirmed in GH receptor knockout mice, in which we observed a robust fasting-induced rise in FFA. We further illustrate the dynamic relationship between the orexigenic and anorexigenic hormones ghrelin and leptin during fasting in the mouse. Our findings show an initial suppression of leptin and the eventual rise in circulating levels of acyl-ghrelin with fasting. However, altered acyl-ghrelin and leptin secretion occurs well after the rise in FFA and the suppression of GH secretion. Consequently, we conclude that although acyl-ghrelin and leptin may modulate the physiological response to drive food intake, these changes do not contribute to the initial loss of pulsatile GH secretion. Rather, it appears that the suppression of GH secretion in fasting may occur in response to an elevation in fasting levels of FFA or physiological stress. Observations highlight a divergent role for GH in modulating FFA release between man and mouse.